联合高血压药物的全球消费模式:2010-2021年制药销售数据的分析
Sahan Jayawardana1, Allen Campbell2, Murray Aitken2
1Department of Health Policy, LSE Health, London School of Economics and Political Science, London, United Kingdom.
PLOS global public health
|September 6, 2024
概括
全球高血压药物消费量正在上升,组合疗法使用量增加,特别是在低收入和中等收入国家 (LMICs). 然而,在全球范围内,吸收仍然不一致.
科学领域:
- 心血管医学 心血管医学
- 全球健康 全球健康
- 药物经济学 药物经济学
背景情况:
- 高血压是导致心血管疾病和死亡的全球主要危险因素,影响了13亿成年人.
- 低收入和中等收入国家 (LMICs) 在高血压控制方面面临着日益扩大的差异和快速增加的高血压率.
- 管理高血压是复杂的,因为多种药物类别和剂量表,突出需要有效的治疗策略.
研究的目的:
- 分析组合与非组合抗高血压药物的全球消费趋势.
- 为了比较2010年至2021年不同国家收入群体 (高收入,中高收入和LMICs) 的消费模式.
- 评估与整体抗高血压药物使用相关的组合抗高血压药物的全球吸收和比例.
主要方法:
- 利用来自IQVIA MIDAS数据库的药品销售数据,涵盖75个国家和2个地区 (2010-2021年).
- 标准化抗高血压药物消费率使用标准单位 (SU) 每1000名居民每天.
- 分析了按国家收入分类 (HIC,UMIC,LMIC) 分层的消费数据.
主要成果:
- 全球每1000名居民每天所有抗高血压药物的平均消费量从2010年的184.78个单位升至2021年的325.6个单位.
- 在所有收入群体中,组合和非组合抗高血压药物的消费量都增加了.
- 与UMICs (24.3%) 和HICs (24.4%) 相比,LMICs的组合抗高血压药使用比例较高 (2021年为45.5%).
结论:
- 组合抗高血压药物,尽管对坚持和疗效的潜在好处,显示不一致的全球吸收.
- 高收入国家 (HICs) 显示,尽管整体抗高血压药物使用量较高,但组合药物的相对消费量较低.
- 低至中产国家的联合抗高血压药物使用趋势越来越强,这表明治疗偏好可能发生转变.
相关概念视频
01:18Hypertension and Regulation of Blood Pressure
2.0K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.0K
01:28Factors affecting Blood pressure
3.0K
Several physiological and lifestyle factors influence blood pressure (BP). Understanding these factors is crucial as they are significant in patient education and blood pressure management.
Physiological Factors:
Physiological Factors:
3.0K
01:28Antihypertensive Drugs: Types of β-Blockers
604
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
604
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
614
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
614
01:17Antihypertensive Drugs: Action of β1 Blockers
327
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
327
01:15Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
49
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
49